

# Xuxu Gou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4539366/publications.pdf>

Version: 2024-02-01

10  
papers

402  
citations

1040056

9  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

827  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Graphene-promoted 3,4,9,10-perylenetetracarboxylic acid nanocomposite as redox probe in label-free electrochemical aptasensor. <i>Biosensors and Bioelectronics</i> , 2011, 30, 123-127.                                     | 10.1 | 63        |
| 2  | Endocrine therapy resistance: new insights. <i>Breast</i> , 2019, 48, S26-S30.   | 2.2  | 60        |
| 3  | Electrochemical aptasensor based on the dual-amplification of G-quadruplex horseradish peroxidase-mimicking DNAzyme and blocking reagent-horseradish peroxidase. <i>Biosensors and Bioelectronics</i> , 2011, 26, 4236-4240. | 10.1 | 59        |
| 4  | MicroRNA-26b Modulates the NF- $\kappa$ B Pathway in Alveolar Macrophages by Regulating PTEN. <i>Journal of Immunology</i> , 2015, 195, 5404-5414.   | 0.8  | 51        |
| 5  | Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. <i>Archives of Biochemistry and Biophysics</i> , 2015, 566, 49-57.   | 3.0  | 50        |
| 6  | EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis. <i>Physiological Reports</i> , 2016, 4, e12915.   | 1.7  | 49        |
| 7  | The effects of microRNAs on glucocorticoid responsiveness. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1005-1011.   | 2.5  | 32        |
| 8  | ESR1 fusions drive endocrine therapy resistance and metastasis in breast cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1526005.   | 0.7  | 16        |
| 9  | Repeated Exposure to <i>Streptococcus pneumoniae</i> Exacerbates Chronic Obstructive Pulmonary Disease. <i>American Journal of Pathology</i> , 2019, 189, 1711-1720.   | 3.8  | 12        |
| 10 | Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. <i>Cancer Research</i> , 2021, 81, 6259-6272.                                       | 0.9  | 10        |